Aleksander Krag
@AleksanderKrag
Professor of Hepatology @SUND_SDU @OUHhospital Director Odense Liver Research Centre @FLASH_OUH
All you need to know about Steatotic Liver Disease! @TheLancet Seminar on SLD👇 A clinician-centered guide covering all from epidemiology, nomenclature, natural history, diagnosis and treatment to healthcare pathways. thelancet.com/journals/lance… #ManolisTsochatzis @FrancqueSven
The 2025 EASL #SLDsummit content is now available on demand is now accessible on demand for all users with a MyEASL account. Re-discover the sessions and ePosters on EASL Campus! 🔗 easlcampus.eu/list-search-ta… #LiverX #LiverTwitter
EASL joins the global hepatology community in mourning the passing of Prof. Jaime Bosch, a visionary clinician-scientist, educator, and leader whose legacy has shaped our field over the past five decades. From pioneering research in portal hypertension to mentoring generations…
New Review - Screening for advanced steatotic liver disease thelancet.com/journals/langa… @AleksanderKrag #LiverTwitter #MedTwitter
To Screen—or not to screen for for advanced steatotic liver disease? Our new @LancetGastroHep review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria @Stine_Johansen_ authors.elsevier.com/c/1lRV98nByrGW…
Saddened to hear about the passing of Jaime Bosch. A true giant in the field!! Incredible passion and commitment until the very end. My thoughts go to @docberza 😔
With deep sadness, we share the passing of Dr. Jaime Bosch — a visionary researcher, passionate physician, and cherished friend. Widely regarded as the father of portal hypertension, the Liver Unit of Barcelona will always be indebted to his immense legacy.
In today’s #readoftheweek📚 from @karolinskainst, learn how paediatric obesity enhances the risk in individuals who had alcohol use disorders during adolescence or young adulthood. Read here this @JHEP_Reports article: jhep-reports.eu/article/S2589-… #LiverX #LiverTwitter
Happy to share this RCT from @LiverGALAXY in people with ALD Out today in @NaturePortfolio rdcu.be/eujFT The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial
INASL-2025 Chandigarh - 7-10th August, 2025 Best of EASL-2025 at INASL 8th August, 2025 Register Now- inasl2025.com @drsuniltaneja @docMPK @drnipunverma @doc_arka @naveendandia @drbabupgi @HepatologyPGI @EASLnews @EASLedu @AleksanderKrag @MattiasMandorf1 @massimoiava
INASL-2025 7th - 10th August, 2025 Chandigarh Best of EASL-2025 at INASL 8th August (Friday)
You asked for more time to complete your application for the EASL–AASLD Masterclass 2025 — and we’re giving it to you. 🗓️ The new deadline is 13 July 2025! Take this extra time to perfect your application and get ready for an unforgettable learning experience! 🔗…
Alcohol use is widespread. 72% of U.S. adults drank weekly in 2019–2020, and consumption rose during the pandemic. Recent discussions highlight that even low levels of alcohol can increase cancer risk, starting at about 1 drink/day for some cancers. There’s no clear “safe”…
Adoption of the New Nomenclature of MASLD by INASL - Implications on it's previous guidelines on NAFLD. Now available on PubMed pubmed.ncbi.nlm.nih.gov/40535844/ @AASLDtweets @AASLDPresident @EASLnews @EASLedu @marurinella @KanwalFasiha @AleksanderKrag @DebbieShawcros1 @JVLazarus
INASL-2025 Chandigarh - 7-10th August, 2025 Postgraduate Course on - Basics and Advances of Hepatology 8th August, 2025 Register Now- inasl2025.com @drsuniltaneja @docMPK @drnipunverma @doc_arka @naveendandia @drbabupgi @HepatologyPGI @EASLnews @EASLedu
INASL-2025 7th - 10th August, 2025 Chandigarh Postgraduate Course - 8th August (Friday)
EMJ Hepatology is out now! 🔗hubs.la/Q03sQxWT0 Inside, uncover all you need to know from #EASL2025 and beyond - including expert interviews with @EASLnews leaders @AleksanderKrag and @DebbieShawcros1, insights on siRNA and much more.
📢Our new Impact Factor is 33.0🎉 🥇Ranking number 1 in the Hepatology field once again! 👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕ @EASLnews @EASLedu #LiverTwitter
Thank you for help unpacking and discussing this important topic that evolves so fast at the moment #SLD, care pathways, use of PEth, #Resmetirom, #semaglutide - link 🔗 to episode easlcampus.eu/videos/easl-st… @ArunJSanyalVCU @EASLedu @EASLnews @FattyLiverA @EuropeLiver
ICYMI: I was honored to participate in @EASLedu's recent online presentation, Steatotic Liver Disease Unpacked: Targeting Dynamic Risks. Watch here. #livertwitter @AleksanderKrag @MeenaBBansal #EASLStudio #LiverXhttps://bit.ly/3FWSvI3
Resmetirom was approved for MASH 14 months ago in the US and is likely to gain approval in the EU shortly, with semaglutide close behind. 🩺 Experts are discussing how these approvals changed their clinical practice, and how the first approval opens the gates and clarifies the…
🍷 Given alcohol consumption is often underreported and fluctuates over time, how should clinicians best approach understanding and monitoring alcohol use? 🧪 PEth can be routinely used for accurate, objective monitoring of alcohol intake in #SLD patients. Sometimes, together…
🔴 We are now live with @AleksanderKrag, @MeenaBBansal, Mattias Ekstedt and @ArunJSanyalVCU to discuss state-of-the-art diagnostic approaches in #SLD. 👉🏽 Watch here: easl.eu/easl-studio-ep… @EASLnews
Today's EASL Studio episode will focus on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment. 🗓️ Today, Wednesday 11 June, 18:00 CEST 🔗 easl.eu/easl-studio-ep… @AleksanderKrag @ArunJSanyalVCU #LiverTwitter #LiverX
This week's EASL Studio episode will explore state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. 🗓️ Wednesday 11 June, 18:00 CEST 🔗 easl.eu/easl-studio-ep… @AleksanderKrag @ArunJSanyalVCU…